Today: 18 January 2026
Subscribe
Browse Category

Biotech News 8 January 2026 - 13 January 2026

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

New York, January 13, 2026, 14:47 ET — During regular trading hours Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy. Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan.…
13 January 2026
····
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes…
13 January 2026
···
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and…
12 January 2026
····
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The…
12 January 2026
····
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

New York, Jan 12, 2026, 14:55 EST — Regular session Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab. (Smmttx) Summit’s filing marks its first attempt to introduce ivonescimab to…
12 January 2026
···
Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

New York, January 12, 2026, 05:24 EST — Premarket Mereo BioPharma Group plc shares held steady near $0.49 in U.S. premarket trading Monday, following a strong 28.6% jump to $0.4944 at Friday’s close. (The Wall Street Journal) Timing is key here. The J.P. Morgan Healthcare Conference is set for Jan. 12-15 in San Francisco, a week known for sharp moves…
12 January 2026
···
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

NEW YORK, Jan 10, 2026, 17:43 EST — Market closed. Shares of Amgen Inc. closed down on Friday, marking a second consecutive day of losses as investors prepared for a new batch of healthcare conference updates. The timing is key as deal discussions pick up again with executives and bankers gathering in San Francisco for the J.P. Morgan Healthcare Conference,…
10 January 2026
····
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

New York, January 9, 2026, 15:59 (EST) — Regular session TG Therapeutics (TGTX.O) shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session. The…
9 January 2026
····
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

New York, Jan 9, 2026, 13:59 EST — Regular session Shares of Revolution Medicines climbed on Friday as investors weighed a report that Merck is in talks to buy the cancer-drug developer for up to $32 billion. Revolution was up about 4.3% at $112.00, after touching $125.79 earlier in the session. (Reuters) The chatter matters because Merck is hunting for…
9 January 2026
···
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

New York, January 9, 2026, 13:20 (EST) — Regular session Wave Life Sciences Ltd shares fell about 5.6% on Friday, down 83 cents at $14.00, after trading between $13.99 and $15.09. The drop came even as biotech exchange-traded funds rose, with the SPDR S&P Biotech ETF up about 1% and the iShares Nasdaq Biotechnology ETF up about 0.5%. The move…
9 January 2026
····
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

New York, January 9, 2026, 13:01 EST — Regular session Immunome, Inc. shares jumped on Friday, outpacing a firmer biotech tape. The Nasdaq-listed stock (IMNM) was up 7.4% at $21.97, after trading between $20.71 and $22.00. The move keeps attention on Immunome’s lead drug, varegacestat, being developed for desmoid tumors — non-cancerous growths in connective tissue that can still be…
9 January 2026
····
Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

Abivax stock slides 9% after Sofinnova flags $134m sale plan, with 2026 trial clock ticking

PARIS, Jan 8, 2026, 20:02 (CET) — Market closed Shares in French biotech Abivax SA (ABVX.PA) closed down 9.49% at 99.20 euros on Thursday, after swinging between 112.40 euros at the open and a low of 94.20 euros. The stock slipped back under the 100-euro mark, with volume at about 246,000 shares, after a 6% rise the day before. MarketScreener…
8 January 2026
····
1 2 3 … 12

Stock Market Today

  • TryHard Holdings Valuation Mixed as THH Trades Near $0.96
    January 18, 2026, 10:45 AM EST. TryHard Holdings (THH) trades near $0.9601 after a streak of mixed short-term results. One-day and weekly moves are modest at about 0.87% and 0.97%, with 1- and 3-month gains near 0.94% and 0.88% and YTD around 0.95%. The price action suggests the market is reassessing risk despite the latest close. Valuation shows a Price-to-Sales (P/S) of 2.1x, above the US Entertainment industry average (1.4x) and a peer average (1.8x). With low profit margins and revenue noted as ¥3,538.922, THH is exposed to event, hospitality, and restaurant demand cycles. The question: is THH undervalued or has the market already priced in growth? Readers can review the detailed valuation breakdown for context and risks.
Go toTop